KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Outstanding (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Shares Outstanding data on record, last reported at $170.3 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.16% year-over-year to $170.3 million; the TTM value through Dec 2025 reached $170.3 million, up 2.16%, while the annual FY2025 figure was $170.3 million, 2.16% up from the prior year.
  • Shares Outstanding reached $170.3 million in Q4 2025 per ACAD's latest filing, up from $166.7 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $170.3 million in Q4 2025 and bottomed at $161.0 million in Q4 2021.
  • Average Shares Outstanding over 5 years is $164.9 million, with a median of $164.7 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: increased 0.65% in 2022, then grew 2.16% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $161.0 million in 2021, then grew by 0.65% to $162.1 million in 2022, then grew by 1.6% to $164.7 million in 2023, then grew by 1.25% to $166.7 million in 2024, then rose by 2.16% to $170.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $170.3 million in Q4 2025, $166.7 million in Q4 2024, and $164.7 million in Q4 2023.